PROS
MCID: PK3005
MIFTS: 34

Pik3ca-Related Overgrowth Syndrome (PROS)

Categories: Cardiovascular diseases, Fetal diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Pik3ca-Related Overgrowth Syndrome

MalaCards integrated aliases for Pik3ca-Related Overgrowth Syndrome:

Name: Pik3ca-Related Overgrowth Syndrome 58
Pros 58

Classifications:

Orphanet: 58  
Developmental anomalies during embryogenesis


External Ids:

Orphanet 58 ORPHA530313

Summaries for Pik3ca-Related Overgrowth Syndrome

MalaCards based summary : Pik3ca-Related Overgrowth Syndrome, also known as pros, is related to pik3ca-related overgrowth spectrum and obesity, early-onset, with adrenal insufficiency and red hair. An important gene associated with Pik3ca-Related Overgrowth Syndrome is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha). The drugs Sirolimus and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include breast, testes and prostate.

Related Diseases for Pik3ca-Related Overgrowth Syndrome

Diseases in the Overgrowth Syndrome family:

Eed-Related Overgrowth Ezh2-Related Overgrowth
Pik3ca-Related Overgrowth Spectrum Pik3ca-Related Overgrowth Syndrome

Diseases related to Pik3ca-Related Overgrowth Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1805)
# Related Disease Score Top Affiliating Genes
1 pik3ca-related overgrowth spectrum 11.9
2 obesity, early-onset, with adrenal insufficiency and red hair 11.8
3 acute monoblastic leukemia 11.4
4 megalencephaly-capillary malformation-polymicrogyria syndrome 11.4
5 seborrheic dermatitis 11.4
6 prolidase deficiency 11.4
7 lipoid congenital adrenal hyperplasia 11.4
8 factor xiii deficiency 11.4
9 tuftsin deficiency 11.1
10 megacystis-microcolon-intestinal hypoperistalsis syndrome 11.1
11 ectodermal dysplasia and immunodeficiency 2 11.1
12 steel syndrome 11.1
13 lambda 5 deficiency 11.1
14 factor v leiden thrombophilia 11.1
15 prostate cancer 10.9
16 neuroblastoma 10.9
17 lung cancer 10.9
18 cytokine deficiency 10.8
19 follicular lymphoma 10.7
20 overgrowth syndrome 10.4
21 ischemia 10.4
22 helix syndrome 10.4
23 colorectal cancer 10.4
24 toxic shock syndrome 10.4
25 autoimmune disease 10.4
26 heart disease 10.4
27 ovarian cancer 10.3
28 chronic kidney disease 10.3
29 lymphocytic leukemia 10.3
30 coronary artery anomaly 10.3
31 atherosclerosis susceptibility 10.3
32 inflammatory bowel disease 10.3
33 kidney disease 10.3
34 pre-eclampsia 10.3
35 vascular disease 10.3
36 breast cancer 10.3
37 lung disease 10.3
38 hyperlipoproteinemia, type iii 10.3
39 rapidly involuting congenital hemangioma 10.3
40 acute myocardial infarction 10.3
41 glioblastoma multiforme 10.3
42 congenital lipomatous overgrowth, vascular malformations, and epidermal nevi 10.3
43 arteries, anomalies of 10.3
44 proteasome-associated autoinflammatory syndrome 1 10.3
45 b-cell lymphoma 10.3
46 brittle bone disorder 10.3
47 periodontitis 10.3
48 hepatocellular carcinoma 10.3
49 alzheimer disease 10.3
50 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.3

Graphical network of the top 20 diseases related to Pik3ca-Related Overgrowth Syndrome:



Diseases related to Pik3ca-Related Overgrowth Syndrome

Symptoms & Phenotypes for Pik3ca-Related Overgrowth Syndrome

Drugs & Therapeutics for Pik3ca-Related Overgrowth Syndrome

Drugs for Pik3ca-Related Overgrowth Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 299)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
2
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
3
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
4
Capecitabine Approved, Investigational Phase 4 154361-50-9 60953
5
Nicotine Approved Phase 4 54-11-5 942 89594
6
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
7
Metformin Approved Phase 4 657-24-9 14219 4091
8
Zinc Approved, Investigational Phase 4 7440-66-6 32051
9
Gliclazide Approved Phase 4 21187-98-4 3475
10
Insulin glargine Approved Phase 4 160337-95-1
11
Glucagon Approved Phase 4 16941-32-5
12
Lixisenatide Approved Phase 4 320367-13-3
13
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
14
tannic acid Approved Phase 4 1401-55-4
15
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
16 Neurotransmitter Agents Phase 4
17 Tolterodine tartrate Phase 4 124937-52-6
18 Muscarinic Antagonists Phase 4
19 Cholinergic Antagonists Phase 4
20 Cholinergic Agents Phase 4
21 Antifungal Agents Phase 4
22 Gastrointestinal Agents Phase 4
23 Autonomic Agents Phase 4
24 Central Nervous System Stimulants Phase 4
25 Nicotinic Agonists Phase 4
26 Anti-Ulcer Agents Phase 4
27 Proton Pump Inhibitors Phase 4
28 Antacids Phase 4
29 Anesthetics Phase 4
30 Central Nervous System Depressants Phase 4
31 Glucagon-Like Peptide 1 Phase 4
32 Insulin, Long-Acting Phase 4
33 Anesthetics, Local Phase 4
34 Insulin, Globin Zinc Phase 4
35 insulin Phase 4
36 Hypoglycemic Agents Phase 4
37
Valganciclovir Approved, Investigational Phase 3 175865-60-8 64147
38
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
39
Nintedanib Approved Phase 3 656247-17-5 56843413
40
leucovorin Approved Phase 3 58-05-9 6006 143
41
Hydroxychloroquine Approved Phase 3 118-42-3 3652
42
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
43
Sulfasalazine Approved Phase 3 599-79-1 5353980 5359476
44
Methyltestosterone Approved Phase 2, Phase 3 58-18-4 6010
45
Testosterone Approved, Experimental, Investigational Phase 2, Phase 3 58-22-0, 481-30-1 6013 10204
46
Testosterone undecanoate Approved, Investigational Phase 2, Phase 3 5949-44-0
47
Testosterone enanthate Approved Phase 2, Phase 3 315-37-7 9416
48
Tacrolimus Approved, Investigational Phase 3 104987-11-3 445643 439492 6473866
49
Adalimumab Approved Phase 3 331731-18-1 16219006
50
Iron Approved, Experimental Phase 3 7439-89-6, 15438-31-0 23925 27284

Interventional clinical trials:

(show top 50) (show all 400)
# Name Status NCT ID Phase Drugs
1 A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients Completed NCT01895335 Phase 4 Teriflunomide
2 A Pilot Study of the Effects of Neutropenia on Patient Reported Outcomes During Chemotherapy With or Without Neulasta® (Pegfilgrastim) in Subjects With Advanced NSCLC Completed NCT00115206 Phase 4 Neulasta® (pegfilgrastim)
3 Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder (Phase Ⅳ) Completed NCT00836381 Phase 4 Tolterodine extended-release (ER) 4mg;Placebo
4 An Open Label, randomIzed Controlled Prospective Multicenter Two Arm Phase IV Trial to Determine Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab for Advanced (Inoperable or Metastatic) HER2-negative Hormone Receptor Positive Breast Cancer Completed NCT02248571 Phase 4 Bevacizumab;Capecitabine;Everolimus;Exemestane
5 Identifying Optimal, Translatable Smoking Cessation Intervention Components Completed NCT01122238 Phase 4 Nicotine Patch;Nicotine Gum;Nicotine Patch + Nicotine Gum
6 The Influence of CYP2C19 Genetic Polymorphism and Dosage of Rabeprazole on the Accuracy of Proton-Pump Inhibitor Testing in Chinese Patients With Gastroesophageal Reflux Disease Completed NCT00354757 Phase 4 rabeprazole
7 Variability of Glucose Assessed in a Randomized Trial Comparing the Initiation of A Treatment Approach With Biosimilar Basal Insulin Analog Or a Titratable iGlarLixi combinatioN in Type 2 Diabetes Among South Asian Subjects (VARIATION 2 SA Trial) Recruiting NCT03819790 Phase 4 Basal insulin glargine and lixisenatide;Basal insulin Basaglar/Lantus + gliclazide MR;Metformin
8 Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib — a Randomized, Controlled Trial Recruiting NCT03735758 Phase 4 pazopanib or guideline conform chemotherapy
9 Interscalene Single Shot With Plain Bupivacaine Versus Liposomal Bupivacaine for Arthroscopic Shoulder Surgery Recruiting NCT03638960 Phase 4 Bupivacaine liposome;Bupivacaine Hydrochloride
10 An Open-Label, Single-Arm Phase IV Study To Assess Ocrelizumab Efficacy, Safety, And Impact On Patient Reported Outcomes (PROS) In Patients With Active Relapsing Multiple Sclerosis Active, not recruiting NCT03589105 Phase 4 Ocrelizumab 300 mg;Ocrelizumab 600 mg
11 A Multicenter, Open-label Phase IV Study to Evaluate Whether a Medication Event Monitoring System (MEMS®) Can Improve Adherence to Tecfidera® (Delayed-release Dimethyl Fumarate) Treatment in Multiple Sclerosis Patients. Terminated NCT02343159 Phase 4 dimethyl fumarate
12 Tight Intra-Operative Glucose Control Using Continuous Insulin Infusion During Coronary Artery Bypass Surgery: Randomized Controlled Trial Terminated NCT00394303 Phase 4 Intraoperative continuous insulin infusion
13 A Multicenter, Open-Label Study to Evaluate Fatigue in Subjects With Relapsing-Remitting Multiple Sclerosis During Treatment With Tecfidera® (Dimethyl Fumarate) Gastro-Resistant Hard Capsules (TECNERGY) Withdrawn NCT02090348 Phase 4 dimethyl fumarate
14 Community Interventions in Non-Medical Settings to Increase Informed Decision Making for Prostate Cancer Screening - Harvard - SIP 21-04 Unknown status NCT00207636 Phase 3
15 Efficacy and Safety of Anti-cytomegalovirus Prophylaxis Versus Pre-emptive Approaches With Valganciclovir in Heart Transplant Recipients Treated With Everolimus or Mycophenolate. A Randomized Open-label Study for Prevention of Cardiaca Allograft Vasculopathy Unknown status NCT00966836 Phase 3 Pre-emptive strategy with valganciclovir plus everolimus;Prophylaxis with valganciclovir plus mycophenolate;Prophylaxis with valganciclovir plus everolimus;Pre-emptive mycophenolate
16 A Six Month Double Blind Randomized Placebo Controlled Trial Followed by Each Arm Being Converted to Oral Nintedanib 150 mg Twice Daily Comparing the Effect on High Resolution Computerized Tomography Quantitative Lung Fibrosis Score, Lung Function, Six Minute Walk Test Distance and St. George's Respiratory Questionnaire After Six Months of Treatment in Patients With Idiopathic Pulmonary Fibrosis With Continued Evaluations Over a Period of up to Eighteen Months Completed NCT01979952 Phase 3 Matching Placebo;Nintedanib
17 A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing the Efficacy and Safety of Sarilumab Added to Non-biologic DMARD Therapy in Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intolerant of TNF-α Antagonists Completed NCT01709578 Phase 3 Sarilumab;placebo;hydroxychloroquine;methotrexate;sulfasalazine;leflunomide
18 New Acute Treatment for Stroke - The Effect of Remote PERconditioning Completed NCT00975962 Phase 3 Actilyse
19 Ph3, Open Label, Multi-Ctr, Pros, Rand Study -Efficacy and Safety, Conversion Prograf® Capsules BID to LCPTacro Tablets QD, for Prevent of Acute Allograft Rejection in Stable Kidney Transplant pt. Completed NCT00817206 Phase 3 LCP-Tacro;Prograf
20 Ph3,DB/DD,Multi-Ctr,Pros,Rand Study-Efficacy and Safety of LCP-Tacro™ Tablets, QD, Compared to Prograf® Capsules,BID, in Combination With Mycophenolate Mofetil for Acute Allograft Rejection in De Novo Kidney Transplant Completed NCT01187953 Phase 3 Prograf (tacrolimus);LCP-Tacro
21 Dose Response Effects of Exogenous Testosterone on the Prostate and Comparison With Effects on Body Composition (Short Title: PROS-2) Completed NCT01327495 Phase 2, Phase 3 Testosterone 1% gel 1.25 g;Testosterone 1% gel 2.5 g;Testosterone 1% gel 5.0 g;testosterone 1% gel 10 g;testosterone 1% gel 15 g;Acyline
22 Telephone and Web-based Teen Tobacco Cessation in HMOs Completed NCT00311948 Phase 3
23 Efficacy/Effectiveness of Unhealthy Drug Use Screening/Brief Intervention Models Completed NCT00876941 Phase 3
24 ASPIRE: DETERIMINING THE IMPACT OF CRISABOROLE (Eucrisa) AND TACROLIMUS 0.03% ON PATIENT-REPORTED OUTCOMES AND CAREGIVER BURDEN IN CHILDREN WITH ATOPIC DERMATITIS Recruiting NCT03645057 Phase 3 Crisaborole;Tacrolimus 0.03% Ointment
25 A Phase 3, 56-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Utilizing Patient-Reported and Radiographic Outcomes to Evaluate the Efficacy and Safety of a Single Injection of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects Recruiting NCT03928184 Phase 3 Lorecivivint;Placebo
26 A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to That of Adalimumab in the Treatment of Biologic Naïve Subjects With Moderately-to-Severely Active Crohn's Disease Recruiting NCT03464136 Phase 3
27 Clinical, Radiological and Patient Perceived Outcome After Total Wrist Arthroplasty With a New Total Wrist Arthroplasty Implant Recruiting NCT02336009 Phase 2, Phase 3
28 Multicenter Randomized Study on the Efficacy of Intravenous Iron Injection in Cancer Patients With Anemia Recruiting NCT04187716 Phase 3 Ferinject
29 A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Recruiting NCT03782376 Phase 3 Ustekinumab approximately 6 mg/kg (IV);Placebo (SC);Placebo (IV);Ustekinumab 90 mg (SC) Group 1;Ustekinumab 90 mg (SC) Group 2
30 Pros & Cons of Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1 in Intensive Care Unit. Recruiting NCT03455322 Phase 2, Phase 3 norepinephrine versus midodrine & octreotide
31 Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer (Study SWOG/NRG 1806) Recruiting NCT03775265 Phase 3 Atezolizumab;Cisplatin;Fluorouracil;Gemcitabine;Mitomycin
32 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis Active, not recruiting NCT03912259 Phase 3 dupilumab SAR231893;placebo;Emollient (moisturizer)
33 A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Children 6 to <12 Years of Age With Uncontrolled Persistent Asthma Active, not recruiting NCT02948959 Phase 3 Dupilumab;Placebo;Asthma Controller Therapies (incl. prednisone/prednisolone);Asthma Reliever Therapies
34 A Phase 3, Randomized, Active Controlled Study to Evaluate Maintenance of Response, Safety and Patient Reported Outcomes in Acromegaly Patients Treated With Octreotide Capsules vs. Parenteral Somatostatin Receptor Ligands Active, not recruiting NCT02685709 Phase 3 Octreotide capsules;Injectable Somatostatin Analogs (octreotide or lanreotide);Cabergoline
35 A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer Suspended NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
36 The Efficacy of Intravenous Iron for the Treatment of Anemia in Cancer Patients Unknown status NCT02599012 Phase 2 Ferinject®
37 Phase 1 Study of Herb Yuyang Ointment That Expressed Good Effect in Diabetic Foot Ulcer Unknown status NCT00839865 Phase 2 herb ointment
38 Adaptation and Evaluation of the Honest Open Proud Program for Adolescents With Mental Illness Completed NCT02751229 Phase 2
39 BrUOG-PROS-221 Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer: A Phase II Study Completed NCT00828308 Phase 2 Ixabepilone
40 Nonrandomized Open Label Pilot Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation Completed NCT02428296 Phase 2 Sirolimus
41 HealthCall: Brief Intervention to Reduce Drug Use in HIV Primary Care Completed NCT01312181 Phase 2
42 Phase II Study of Comprehensive Patient Reported Outcomes (PRO) Management for Oncology Practice Completed NCT01108315 Phase 1, Phase 2
43 Computer-based Brief Intervention for Perinatal Drug, Alcohol, and Tobacco Abuse Completed NCT00685074 Phase 1, Phase 2
44 Phase II Randomized Controlled Trial of Rapid and Easy Strength Training to Preserve Function in Late Stage Cancer Completed NCT01334983 Phase 2
45 Feasibility, Efficacy and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Cisplatin and Doxorubicin in Patients With Gastric Cancer and Peritoneal Carcinomatosis: an Open-label, Single-arm, Phase II Clinical Trial Completed NCT01854255 Phase 2 doxorubicin and cisplatin
46 Project CHOICES Efficacy Study for Preventing Alcohol-Exposed Pregnancies Completed NCT00153478 Phase 2
47 A Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Clinical Effect of Oral Danirixin (GSK1325756) in the Treatment of Healthy Adults With Acute, Uncomplicated Influenza (201682) Completed NCT02469298 Phase 2 GSK1325756 (Danirixin);Placebo To Match GSK1325756;Oseltamivir Phosphate;Placebo To Match Oseltamivir Phosphate
48 Biomarkers of Lupus Disease: Study of Biomarker Changes Before and After Treatment With Depomedrol and Background Medication Withdrawal in Patients With Mild to Moderate SLE Disease Activity Completed NCT00987831 Phase 1, Phase 2 Group A SLE prospective study
49 Alcohol Use Reduction in Methadone Individuals With HCV Completed NCT00958763 Phase 2
50 Screening and Brief Intervention in the ED Among Mexican-origin Young Adults Completed NCT02056535 Phase 2

Search NIH Clinical Center for Pik3ca-Related Overgrowth Syndrome

Genetic Tests for Pik3ca-Related Overgrowth Syndrome

Anatomical Context for Pik3ca-Related Overgrowth Syndrome

MalaCards organs/tissues related to Pik3ca-Related Overgrowth Syndrome:

40
Breast, Testes, Prostate, Lung, Heart, Brain, Kidney

Publications for Pik3ca-Related Overgrowth Syndrome

Articles related to Pik3ca-Related Overgrowth Syndrome:

(show top 50) (show all 10273)
# Title Authors PMID Year
1
Treatment of hyperphosphatemia: the dangers of high PTH levels. 61
31696357 2020
2
Treatment of hyperphosphatemia: the dangers of aiming for normal PTH levels. 61
31823044 2020
3
Human papillomavirus vaccination and prevention of intraepithelial neoplasia and penile cancer: review article. 61
31972636 2020
4
Advances in controlled release pesticide formulations: Prospects to safer integrated pest management and sustainable agriculture. 61
31740313 2020
5
Long-Term Patient-Reported Outcomes After High-Dose Chemoradiation Therapy for Nonsurgical Management of Distal Rectal Cancer. 61
31707122 2020
6
Scrambler therapy for chemotherapy neuropathy: a randomized phase II pilot trial. 61
31209630 2020
7
Preventing Ovarian Cancer in High-risk Women: One Surgery at a Time. 61
31764001 2020
8
Depression, sleep disturbances, pain, disability and quality of LIFE in Brazilian Fabry disease patients. 61
31871893 2020
9
Pilot randomized trial of an electronic symptom monitoring and reporting intervention for hospitalized adults undergoing hematopoietic stem cell transplantation. 61
31222392 2020
10
Prospective development of a patient-reported outcomes instrument for desmoid tumors or aggressive fibromatosis. 61
31691276 2020
11
Clinical manifestations, disease activity and disease burden of radiographic versus non-radiographic axial spondyloarthritis over 5 years of follow-up in the DESIR cohort. 61
31784451 2020
12
Molecular Imaging of Cardiovascular Device Infection: Targeting the Bacteria or the Host-Pathogen Immune Response? 61
32034110 2020
13
Patient-reported Outcomes Following Treatment of Localised Prostate Cancer and Their Association with Regret About Treatment Choices. 61
31411965 2020
14
Perioperative monitoring of inguinal hernia patients with a smartphone application. 61
31542838 2020
15
Patient-Reported Outcomes and Evidence-Based Practice in Speech-Language Pathology. 61
32011905 2020
16
Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection. 61
31376493 2020
17
Pros and cons in prion diseases abatement: Insights from nanomedicine and transmissibility patterns. 61
31866542 2020
18
Immunotherapy approaches for peanut allergy. 61
31928251 2020
19
The National Psoriasis Foundation Psoriasis Treatment Targets in Real World Patients: Prevalence and Association with Patient Reported Outcomes in the Corrona Psoriasis Registry. 61
32027420 2020
20
Do preoperative patient-reported outcomes predict hospital length of stay for surgically-treated end-stage ankle osteoarthritis patients? 61
30773458 2020
21
The effect of perioperative anesthetics for prevention of postoperative delirium on general anesthesia: A network meta-analysis. 61
31284222 2020
22
Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report. 61
32007210 2020
23
Postoperative Outcomes Based on American Society of Anesthesiologists Score After Minimally Invasive Transforaminal Lumbar Interbody Fusion. 61
31913170 2020
24
Helminths Turning on the NLRP3 Inflammasome: Pros and Cons. 61
31753545 2020
25
Current state of WSI use in cytopathology: pros and pitfalls. 61
32020667 2020
26
Commentary: Teleophthalmology and electronic medical records: Weighing the pros and cons of unavoidable progress. 61
31957729 2020
27
Assessing the One-Bond Cα-H Spin-Spin Coupling Constants in Proteins: Pros and Cons of Different Approaches. 61
31928007 2020
28
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. 61
32035514 2020
29
[Self-determination despite dementia! Participant protection instead of incapacitation in research : Report on the 5th Ethics Conference of the German Center for Neurodegenerative Diseases]. 61
31915864 2020
30
A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer. 61
32011193 2020
31
Adjuvant chemotherapy for rectal cancer: Current evidence and recommendations for clinical practice. 61
31955069 2020
32
Alcohol Use and Ethnicity Independently Predict Antiretroviral Therapy Nonadherence Among Patients Living with HIV/HCV Coinfection. 61
31435855 2020
33
Price Models for Multi-indication Drugs: A Systematic Review. 61
31523756 2020
34
Frequency, Determinants, and Satisfaction of Breast Augmentation in Trans Women Receiving Hormone Treatment. 61
31806494 2020
35
Integration of patient-reported outcomes (PROs) for personalized symptom management in "real-world" oncology practices: a population-based cohort comparison study of impact on healthcare utilization. 61
32020357 2020
36
Vaccine hesitancy and influenza beliefs among parents of children requiring a second dose of influenza vaccine in a season: An American Academy of Pediatrics (AAP) Pediatric Research in Office Settings (PROS) study. 61
32017643 2020
37
Capturing the patient voice: implementing patient-reported outcomes across the health system. 61
31606809 2020
38
Static Versus Expandable Devices Provide Similar Clinical Outcomes Following Minimally Invasive Transforaminal Lumbar Interbody Fusion. 61
32015740 2020
39
Including the patient voice in the development and implementation of patient-reported outcomes in cancer clinical trials. 61
31722131 2020
40
Data on patient-reported outcomes and the risk of readmission following a cardiac diagnosis. 61
31871998 2020
41
The hidden information in patient-reported outcomes and clinician-assessed outcomes: multiple sclerosis as a proof of concept of a machine learning approach. 61
31659583 2020
42
A Randomized Pilot Study of Mindfulness-Based Stress Reduction in a Young Adult Cancer Sample: Feasibility, Acceptability, and Changes in Patient Reported Outcomes. 61
32040222 2020
43
Integration of Patient Reported Outcomes in Drug Development in Genitourinary Cancers. 61
32036478 2020
44
Collection of Common Knee Patient-reported Outcome Instruments by Automated Mobile Phone Text Messaging in Pediatric Sports Medicine. 61
31107346 2020
45
An Intact Ligamentum Teres Predicts a Superior Prognosis in Patients With Borderline Dysplasia: A Matched-Pair Controlled Study With Minimum 5-Year Outcomes After Hip Arthroscopic Surgery. 61
32017862 2020
46
Post-traumatic elbow stiffness: Pathogenesis and current treatments. 61
32010232 2020
47
Return to Play in Amateur Soccer Players Undergoing Hip Arthroscopy: Short- to Mid-Term Follow-Up. 61
31866280 2020
48
Correlations of Single-Leg Performance Tests to Patient-Reported Outcomes After Primary Anterior Cruciate Ligament Reconstruction. 61
32032156 2020
49
Prospective Collection of PROMIS Physical Function Measure Demonstrates Significant Improvement After Bariatric Surgery. 61
32030612 2020
50
Preoperative opioid use is associated with inferior outcomes after patellofemoral stabilization surgery. 61
31650313 2020

Variations for Pik3ca-Related Overgrowth Syndrome

Expression for Pik3ca-Related Overgrowth Syndrome

Search GEO for disease gene expression data for Pik3ca-Related Overgrowth Syndrome.

Pathways for Pik3ca-Related Overgrowth Syndrome

GO Terms for Pik3ca-Related Overgrowth Syndrome

Sources for Pik3ca-Related Overgrowth Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....